Atea Pharmaceuticals Inc

NASDAQ:AVIRUnited States

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The Company is engaged in is conducting a Phase 3 clinical trial evaluating bemnifosbuvir for the treatment of Coronavirus disease 2019 (COVID-19). It is also conducting a Phase 2 clinical trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). The bemnifosbuvir (AT-527), is an investigational, novel, orally administered guanosine nucleotide analog polymerase inhibitor that combines a unique nucleotide scaffold with novel double prodrugs for the intended purpose of inhibiting the enzymes central to viral replication. SUNRISE-3 is designed to evaluate bemnifosbuvir as monotherapy, but it is also exploring the effect of combination therapy in a smaller sub-set of patients.

Contact Information

Headquarters

225 Franklin Street, Suite 2100BOSTON, MA, United States 02110

Phone

857-204-8109

Fax

302-655-5049

Executives

Chairman of the Board, President, Chief Executive Officer, Founder

Jean-Pierre Sommadossi

Chief Financial Officer, Executive Vice President - Legal , Secretary

Andrea Corcoran

Executive Vice President, Chief Accounting Officer

Wayne Foster

Chief Development Officer

Janet Hammond

Chief Medical Officer

Maria Horga